Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32)

Abstract

Aims/IntroductionSix kinds of oral antidiabetic drugs (OADs), including the new dipeptidyl peptidase 4 (DPP‐4) inhibitors, are available. The present study aimed to define trends within the prescribing patterns of OADs, as well as changes in glycemic control in Japan over a 10‐year period from 2002 to 2011.Materials and MethodsWe carried out a cross‐sectional study using data of type 2 diabetes mellitus patients from 24 clinics for 2002, 2005, 2008 and 2011. OAD use was analyzed combined with clinical data.ResultsSulfonylureas (SUs) were the most commonly used OAD, but their use for monotherapy markedly decreased over the study period. Biguanides (BGs) were the second most commonly used OAD, and their prescribing rate increased both for mono‐ and combination therapy. DPP‐4 inhibitors (DPP‐4I), released in 2009, were the third most commonly prescribed OAD in 2011 both for mono‐ and combination therapy. Among combination therapies, two OADs were mostly prescribed, but the use of three OADs and four OADs in 2011 was two‐ and 14.8‐fold those in 2002. These trends were accompanied by an improvement in average glycated hemoglobin from 7.5 ± 1.2% in 2002 to 7.1 ± 0.9% in 2011.ConclusionsThe OAD prescribing trend has moved away from monotherapy with SUs and toward combination therapies to achieve better glycemic control. Increased use of BGs and DPP‐4I was predominant in 2011. These trends were accompanied by an improvement of the glycated hemoglobin level.

Drug Utilization Evaluation of Antidiabetic Drugs Among Type 2 Diabetes Patients of Tamil Nadu

“…The study documented higher number of DPP-4 inhibitors such as vildagliptin (9.52%) prescribed. DPP-4 inhibitors use has greatly increased with uncontrolled overweight/obese; this result is in agreement with other reports conducted worldwide [12][13][14]. Another study carried out by Tolba et al, vildagliptin as an add-on therapy to gliclazide was not associated with the cardiovascular risks and showed the significant reduction in the hemoglobin A1c and fasting blood sugar [15].…”

Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study

“…When compared to patients who planned to start first-time insulin therapy [15] or those using oral hypoglycemic agents (OHA) alone [16], the following features were observed in this cohort: better glycemic control than patients considering insulin injections [15], but not better than those using OHA alone [16]; younger; shorter duration of T2DM; and higher BMI [19]. With regard to high BMI, obese T2DM patients with poor glycemic control in OHA therapy seemed to have been selected as candidates for this study in the hope of weight loss via liraglutide [17].…”

Control Status of Atherosclerotic Cardiovascular Risk Factors Among Japanese High-Risk Subjects:Analyses of a Japanese Health Check Database from 2008 to 2011

“…Several studies surveying the control status of lipids and BP in Japanese patients have been reported [12][13][14][15] ; however, these studies targeted only those who had been taking medications for lipids or BP, suggesting that the results of these studies do not reflect the overall control status including those who are not on medication. The Japan Diabetes Clinical Data Management (JDDM) Group has been analyzing the status of glycemic control in diabetic patients since 2002 16) ; however, at present, no such data have been available in subjects with pCHD and pCVD in Japan. The Ministry of Health, Labour and Welfare of the Japanese government annually performs National Health and Nutrition Examination Survey by randomly selecting approximately 6,000-10,000 subjects from the general Japanese population and releases the data on its homepage 17) ; however, understandably, no data are available on the control status in those who are at high risk of atherosclerotic diseases.…”